vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $173.1M, roughly 1.2× VARONIS SYSTEMS INC). IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $49.0M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.
IDYA vs VRNS — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $173.1M |
| Net Profit | $119.2M | — |
| Gross Margin | — | 76.0% |
| Operating Margin | 52.2% | -1.7% |
| Net Margin | 57.4% | — |
| Revenue YoY | — | 26.9% |
| Net Profit YoY | 330.1% | — |
| EPS (diluted) | $1.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $173.1M | ||
| Q4 25 | — | $173.4M | ||
| Q3 25 | $207.8M | $161.6M | ||
| Q2 25 | — | $152.2M | ||
| Q1 25 | — | $136.4M | ||
| Q4 24 | — | $158.5M | ||
| Q3 24 | $0 | $148.1M | ||
| Q2 24 | $0 | $130.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-27.8M | ||
| Q3 25 | $119.2M | $-29.9M | ||
| Q2 25 | — | $-35.8M | ||
| Q1 25 | — | $-35.8M | ||
| Q4 24 | — | $-13.0M | ||
| Q3 24 | $-51.8M | $-18.3M | ||
| Q2 24 | $-52.8M | $-23.9M |
| Q1 26 | — | 76.0% | ||
| Q4 25 | — | 78.9% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 83.6% | ||
| Q3 24 | — | 83.8% | ||
| Q2 24 | — | 82.8% |
| Q1 26 | — | -1.7% | ||
| Q4 25 | — | -17.5% | ||
| Q3 25 | 52.2% | -22.2% | ||
| Q2 25 | — | -24.0% | ||
| Q1 25 | — | -32.1% | ||
| Q4 24 | — | -11.1% | ||
| Q3 24 | — | -16.0% | ||
| Q2 24 | — | -22.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | -16.0% | ||
| Q3 25 | 57.4% | -18.5% | ||
| Q2 25 | — | -23.5% | ||
| Q1 25 | — | -26.2% | ||
| Q4 24 | — | -8.2% | ||
| Q3 24 | — | -12.4% | ||
| Q2 24 | — | -18.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.23 | ||
| Q3 25 | $1.33 | $-0.26 | ||
| Q2 25 | — | $-0.32 | ||
| Q1 25 | — | $-0.32 | ||
| Q4 24 | — | $-0.12 | ||
| Q3 24 | $-0.60 | $-0.16 | ||
| Q2 24 | $-0.68 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $453.5M |
| Total Assets | $1.2B | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $179.3M | ||
| Q4 25 | — | $883.7M | ||
| Q3 25 | $786.9M | $671.3M | ||
| Q2 25 | — | $770.9M | ||
| Q1 25 | — | $567.6M | ||
| Q4 24 | — | $529.0M | ||
| Q3 24 | $920.0M | $844.8M | ||
| Q2 24 | $701.7M | $582.5M |
| Q1 26 | — | $453.5M | ||
| Q4 25 | — | $598.7M | ||
| Q3 25 | $1.1B | $604.8M | ||
| Q2 25 | — | $341.5M | ||
| Q1 25 | — | $367.7M | ||
| Q4 24 | — | $455.7M | ||
| Q3 24 | $1.2B | $428.6M | ||
| Q2 24 | $931.7M | $458.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $973.7M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $55.0M |
| Free Cash FlowOCF − Capex | $142.2M | $49.0M |
| FCF MarginFCF / Revenue | 68.4% | 28.3% |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $118.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $55.0M | ||
| Q4 25 | — | $24.7M | ||
| Q3 25 | $142.2M | $33.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $68.0M | ||
| Q4 24 | — | $24.3M | ||
| Q3 24 | $-49.2M | $22.5M | ||
| Q2 24 | $-32.9M | $11.7M |
| Q1 26 | — | $49.0M | ||
| Q4 25 | — | $20.7M | ||
| Q3 25 | $142.2M | $30.4M | ||
| Q2 25 | — | $18.0M | ||
| Q1 25 | — | $65.7M | ||
| Q4 24 | — | $19.9M | ||
| Q3 24 | $-49.7M | $21.3M | ||
| Q2 24 | $-33.9M | $10.9M |
| Q1 26 | — | 28.3% | ||
| Q4 25 | — | 12.0% | ||
| Q3 25 | 68.4% | 18.8% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 48.1% | ||
| Q4 24 | — | 12.6% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 8.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
VRNS
| SaaS | $161.1M | 93% |
| Term license subscriptions | $6.9M | 4% |
| Maintenance and services | $5.2M | 3% |
